Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Effect of surgery and radiotherapy on complete blood count, lymphocyte subsets and inflammatory response in patients with advanced oral cancer

  • 1, 2Email author,
  • 3,
  • 1, 2,
  • 1, 2,
  • 1, 2 and
  • 1, 2
BMC Cancer201818:235

https://doi.org/10.1186/s12885-018-4136-9

  • Received: 14 August 2017
  • Accepted: 15 February 2018
  • Published:
Open Peer Review reports

Abstract

Background

The immune system has a known role in the aetiology, progression and final treatment outcome of oral squamous cell cancers. The aim of this study was to evaluate the influence of radical surgery and radiotherapy on advanced oral squamous cell carcinoma blood counts, lymphocyte subsets and levels of acute inflammatory response markers.

Methods

Blood samples were obtained from 56 patients 5 days before and 10 days after surgery, 30 days and 1 year after radiotherapy. The whole blood count, lymphocyte subsets and inflammatory response markers (C-reactive protein, erythrocyte sedimentation rate, leukocyte count, expression of index CD64 and index CD163 on neutrophils and monocytes) were measured, statistically analysed and correlated with clinical treatment outcomes.

Results

The post-operative period was characterised by the onset of anaemia, thrombocytosis, lymphopenia with reduced B lymphocyte, T helper cell and NK cell counts, and a rise in acute phase reactants. Immediately after radiotherapy, the anaemia improved, the lymphopenia worsened, and thrombocyte levels returned to pre-treatment values. There was a drop in counts across the T and B cell lines, including a reduction in B lymphocytes, naïve and memory T cells with reduced CD4+ and CD8+ counts and a decreased CD4/CD8 ratio. One year after radiotherapy all the lymphocyte subsets remained depressed, the only exception being NK cells, whose levels returned to pre-treatment values.

Conclusions

We concluded that surgery resulted in a stronger acute phase response than radiotherapy, while radiotherapy caused a long-lasting reduction in lymphocyte counts. There was no correlation between any of the pre-treatment parameters and the clinical outcome.

Keywords

  • Oral cancer
  • Surgery
  • Radiotherapy
  • Lymphopenia
  • Treatment outcome

Background

Oral and pharyngeal cancer is the 7th most common cancer and the 9th most lethal in the European Union [1]. The treatment for early-stage oral squamous cell cancers (OSCC) is generally single modality, either surgery or radiotherapy. Treatment of early-stage oral squamous cell cancers (OSCC) is generally unimodal using either surgery or radiotherapy (RT). The treatment for locoregionally advanced OSCC is multimodal, with either surgery followed by adjuvant radiation or chemoradiation (as indicated by pathologic features), or definitive chemoradiation. Survival of patients with oral cancer mainly depends on the stage of disease. More than 50% of patients with oral cancer have advanced disease at the time of diagnosis [2]. By introducing new cytotoxic therapies to patients’ treatment regimens, the survival rates have improved in the last decade [3].

Lymphocytes are involved in most human immune system mechanisms aimed at identifying and removing cancer cells [4]. Patients with cancer are known to have abnormalities in T-cell and B-cell counts [5].

The microenvironment of head and neck squamous cell carcinomas (HNSCC), which include OSCC amongst them, is characterized by an imbalanced cytokine profile, favouring immunosuppressive over stimulatory cytokines [6]. It is also known that immunodeficiency increases HNSCC risk [7]. Infiltration of regulatory T cells into the tumour microenvironment was shown to promote tumour-induced immune modulation and subsequent tumour progression [8].

Patients with HNSCC have reduced levels of CD3+, CD4+, and CD8+ T cells in peripheral blood and CD4+ levels show correlation with the stage of disease [9].

Injury from surgical trauma follows dynamic pattern and results in haemodynamic, metabolic and immune changes in patients in the postoperative period. The initial systemic inflammatory response is mediated primarily by the cells of the innate immune system. Once healing of the injured site has begun, an anti-inflammatory response becomes prominent. This anti-inflammatory or immunosuppressive phenotype is mediated primarily by the cells of the adaptive immune system. After major surgery, the functions of innate and of cell- mediated immunity are dramatically paralyzed [10].

Radiotherapy is one of three treatment modalities in oral cancer patients. Depending on the site and dose of radiation majority of patients will experience signs of acute toxicity that are self-limited in duration [11]. Lymphocytes are sensitive to radiation and radiation of areas rich in lymphatics and large vessels produces significant and long lasting immune alterations [12].

The aim of our prospective non-randomized study was to evaluate the effect of major surgical procedures and RT on the complete blood count, lymphocyte subpopulations and acute inflammatory response markers in the peripheral blood of patients with advanced oral squamous cell carcinoma (AOSCC). Partial preliminary results have already been published [13].

Methods

Patients were selected from the prospective non-randomized study, running from 2008 to 2013 on the Clinical Department for Oral and Maxillofacial Surgery, University Clinical Center in Ljubljana, according to the following inclusion criteria:
  • Histologically verified squamous cell carcinoma of the oral cavity Stage III and IV according to the American Joint Committee on Cancer 2010 staging.

  • Surgery and radiotherapy as the only treatment modalities.

  • Patients’ first malignant tumour.

  • No prior radiotherapy.

  • Completed blood sampling prior to surgery, after surgery, after radiotherapy, 1 year after the radiotherapy.

The study protocol was approved by the Republic of Slovenia National Medical Ethics Committee (No. 79/06/07; 19 April 2007), and an adequate written consent was obtained from each patient. Protocol of the study did not affect the standard treatment protocol of the patients in any way. The primary treatment modality of oral cancer is generally determined by the stage of the disease, with surgical treatment remaining the mainstay of multimodal treatment. In treatment selection our multidisciplinary board follows the national guidelines, which were adopted from the National Comprehensive Cancer Network (NCCN).

Seventy two patients were enrolled in the study in line with the inclusion criteria. At the end of the study 10 patients, who had been clinically assigned to advanced cancer, were down staged based on the histopathological report, 4 patients did not have complete blood samples and 2 patients no longer wanted to participate in the study. Of the remaining 56 patients, there were 44 men and 12 women with median age of 68 years (range, 47-89 years). Additional examinations required for the purpose of our study were blood sampling 5 days before surgery (T1), 10 days after surgery (T2), 30 days after radiotherapy (T3) and 1 year after radiotherapy (T4). The treatment outcome was evaluated 2 years after the radiotherapy. Main characteristics of patients are presented in Table 1.
Table 1

The main patient characteristics together with AOC stages, localizations of tumours, type of neck dissection, reconstruction type and blood sampling times

Number of patients

56

Gender

♂ 44

♀ 12

Age (mean (range))

62 (42-84)

Cancer Stage AJCC2010

III (12)

IVA (44)

Tumour location

Tongue

22

Floor of mouth

17

Retromolar trigonum

6

Gum Maxilla

5

Gum Mandible

6

Neck dissection

Unilateral

25

Bilateral

31

Reconstruction

None

 

5

Local flap

Tongue

2

Distal flap

Temporalis

2

PMMF

6

Free flap

RFF

22

ALT

8

Iliac crest

3

Fibula

6

LMF

2

Blood samples

T1- 5 days before surgery

T2- 10 days after surgery

T3- 30 days after radiotherapy

T4- 1 year after radiotherapy

PMMF Pectoralis Major Muscular Flap, RFF Radial Forearm Flap, LMF Latissimus Myocutaneous Flap, ALT Anterior Lateral Thigh, T1 blood sample before surgery, T2 blood sample after surgery, T3 blood sample before radiotherapy, T4 blood sample 1 year after radiotherapy

Flow cytometry: The samples (100 μl of blood) were incubated with 10 μl of the appropriate MoAb. Antibodies against the following cell surface structures were applied: CD3, CD4, CD8, CD19, HLA-DR, CD56, CD45RA+, CD45RO, CD95 (Exalpha Biologicals, Boston, MA, USA. Non-specific isotype mouse MoAb were used as negative controls. Cells were analyzed on FACSCantoII™ Flow Cytometer (BDBiosciences), equipped with blue (488-nm solid-state) and red (633-nm helium-neon) laser. Digital data was acquired with FACSDiva software (BDBiosciences) and analyzed using FlowJo software (Tree Star Inc.).

Neutrophil CD64 expression was measured with a diagnostic kit Leuko64™ following the manufacturer’s instructions. Additionally, we used the Leuko64™ QuantiCALC automated software (Trillium Diagnostic) that reports neutrophil expression of CD64 as an index using fluorescein-labelled calibration beads. An internal negative control of the assay was provided by the automated measurement of the lymphocyte CD64 index, which had to be less than 1.0, and an internal positive control of the assay was provided by automated measurement of the monocyte CD64 index, which had to be more than 3.0. Isotype-control antibodies were routinely used in each experiment to detect a non-specific staining.

Data were presented as the average and 95% confidence interval for the average. Comparison between groups at different time intervals was performed using the Student’s t- test.

One year after last blood sampling (T4), patients were divided into two groups: the first one with no evidence of disease or with death of other cause, and the second with local, locoregional or distal failure and death of the disease. We checked for possible prognostic factors in the immune state of the patients, prior to the performance of a Student’s t-test between these two groups.

The differences were considered to be statistically significant at the level of p < 0.05. Statistical analysis was performed using Statistical Package for the Social Sciences for Windows, version 12.0 (SPSS Inc., Chicago, USA).

Results

Of 56 patients that matched the inclusion criteria, 37 were free of disease at final check-up (1 year after last blood sampling - T4). Of the remaining 19, 4 patients died of other causes during the time of our study, 9 patients died of disease-related complications, 4 patients developed local progression of the disease, 1 patient developed distant metastases, and 1 patient developed a secondary tumour. Thirty seven patients that were free of disease and 4 patients that died of other causes constituted the “success” group, while the remaining 15 patients constituted the “failure” group.

Blood samples prior to surgery (T1) were collected between 5 to 13 days before surgery (mean 8 ± 2). All patients were surgically treated with en-bloc excision of tumour and modified neck dissection (31 of them bilateral), and a subsequent reconstruction (41 with free flaps and 10 with pedicled flaps). In only 5 cases it was possible to close the defect primarily. The average blood loss during surgery was 470 ml (range 250 - 1200 ml) as assessed by the anaesthesiologist and the surgeon. All except one patient were tracheotomised at the time of surgery, with 3 patients subsequently remaining tube dependent, and the remainder having the tracheostomy tube removed between 2 to 22 days after the surgical procedure (mean 8 ± 5).

Blood samples prior to radiotherapy (T2) were taken between 8 and 11 days after surgery (mean 8 ± 2). Patients were irradiated with an external beam by a 6 MV linear accelerator. They received a dose between 60 and 66 Gy (mean 62 ± 2), divided over 2 Gy daily fractions, five times a week. No patient received hyperfractionated RT or chemotherapy. RT was performed within 28 to 54 days after surgery (mean 34 ± 7). The lower border of the irradiation field was always two centimetres above the clavicle, to avoid irradiation of the thymus.

The period of time between the last dose of RT and the next blood sample collection (T3) ranged from 24 to 44 days (mean 36 ± 6). The last blood sample (T4) was collected between 206 and 517 days after radiotherapy (mean 398 ± 57).

The mean values of measured parameters at all blood sampling times are presented in Table 2 together with their standard deviations and normal reference values for peripheral blood of our hospital laboratory.
Table 2

Mean values and standard deviations of all measured parameters in blood samples in observed times (T1, T2, T3, T4) together with normal values

 

T1 (mean ± SD)

T2 (mean ± SD)

T3 (mean ± SD)

T4 (mean ± SD)

Normal values

Erci (10*12/L)

4.32 ± 0.52

3.75 ± 0.48

4.45 ± 0.62

4.33 ± 0.44

4.20- 6.30

Hb (g/L)

139.2 ± 12.6

114.6 ± 17.9

134.9 ± 16.7

135.3 ± 12.2

120-180

Leu. (10*9/L)

8.53 ± 2.81

9.34 ± 3.06

6.9 ± 2.37

7.78 ± 5.39

4.0- 10.0

Lym (10*9/L)

1.9 ± 0.62

1.7 ± 0.62

1.1 ± 0.49

1.24 ± 0.64

1.4- 3.3

Pt (10*9/L)

278.7 ± 83.5

511.6 ± 202.2

270.7 ± 76.3

278.2 ± 92.1

140- 340

Neutr (10/9/l)

5.50 ± 2.26

6.56 ± 2.79

4.99 ± 2.12

5.54 ± 3.99

1.6- 7.5

CRP (mg/L)

9.1 ± 12.2

33.8 ± 37.4

13.3 ± 28.6

11.9 ± 23.8

< 5

ESR (mm/h)

32.1 ± 20.9

59.8 ± 21.2

39.8 ± 25.3

28.2 ± 19.6

< 15

Albumin (g/L)

42.7 ± 3.9

39.1 ± 4.2

43.9 ± 3.9

45.0 ± 3.3

32- 55

iCD64 mono.

7.5 ± 2.5

9.1 ± 3.9

11.0 ± 20.6

8.0 ± 2.9

4.34–8.70

iCD64 nevt.

0.73 ± 0.22

1.09 ± 1.46

0.93 ± 0.58

0.75 ± 0.32

0.45–2.16

iCD163 mono.

8586 ± 4129

8538 ± 4885

8667 ± 5288

8372 ± 6002

1061- 2740

iCD163 nevt.

223.4 ± 109.6

238.5 ± 153.8

252.9 ± 173.3

253.7 ± 172.9

301-435

HLA/DR3 (10*9/L)

0.26 ± 0.19

0.27 ± 0.25

0.28 ± 0.25

0.21 ± 0.21

0.06-0.30

CD3+ (10*9/L)

1.44 ± 0.52

1.32 ± 0.55

0.79 ± 0.41

0.81 ± 0.56

1.00-2.20

CD19+ (10*9/L)

0.17 ± 0.10

0.13 ± 0.07

0.06 ± 0.04

0.10 ± 0.06

0.11-0.57

CD4+ (10*9/L)

0.92 ± 0.32

0.82 ± 0.32

0.37 ± 0.17

0.38 ± 0.22

0.53-1.30

CD8+ (10*9/L)

0.53 ± 0.28

0.50 ± 0.32

0.41 ± 0.29

0.43 ± 0.38

0.33-0.92

CD4/CD8

2.10 ± 1.14

2.12 ± 1.27

1.11 ± 0.64

1.11 ± 0.59

1.0- 2.0

NK (10*9/L)

0.30 ± 0.16

0.24 ± 0.12

0.26 ± 0.14

0.34 ± 0.18

0.07-0.48

CD45RA + CD4+

0.27 ± 0.18

0.22 ± 0.13

0.06 ± 0.04

0.07 ± 0.05

0.23-0.77

CD45RO + CD4+

0.65 ± 0.25

0.59 ± 0.26

0.31 ± 0.15

0.31 ± 0.20

0.24 – 0.70

Legend: Leu leukocytes, Lym lymphocytes, CD3+ T lymphocytes, CD19+ B lymphocytes, CD4+ T helper cells, CD8+ cytotoxic T cells, HLA/DR3 activated T lymphocytes, NK natural killer cells, iCD64 mono index of CD64 expression on monocytes, iCD64 neutr index of CD64 expression on neutrophils, iCD163 mono index of CD163 expression on monocytes, iCD163 neutr index of CD163 expression on neutrophils, CD45 + RA + CD4+ naïve helper T lymphocytes, CD45 + RO + CD4+ memory helper T lymphocytes, CD95 + CD4+ apoptosis destined T helper cells, Erci erythrocytes, Hb haemoglobin, Pt platelets, Neutr neutrophils, ESR erythrocyte sedimentation rate; CRP C-reactive protein

Surgery resulted in anaemia, leucocytosis, lymphopenia, thrombocytosis, rise in neutrophils, CRP, erythrocyte sedimentation rate (ESR) and a reduction in albumin levels. In lymphocyte subpopulations the reductions in B lymphocyte, T helper cell, NK cell and naïve helper T lymphocyte counts were statistically significant. Out of the measured indexes, the only statistically significant increase was in the level of index CD64 on monocytes.

Radiotherapy caused a marked reduction in total lymphocyte counts, the levels of T, B lymphocytes, T helper lymphocytes, and cytotoxic T lymphocytes. CD4+ lymphocytes levels changed more than CD8+ levels, thereby also decreasing the CD4/CD8 ratio. Neither the CD64 index nor CD163 index showed any statistically significant changes during the observational period. The levels of NK cells did not change after radiotherapy and after 1 year rose to levels that were just above the pre-treatment values. CD45RA + CD4+ (naïve) T lymphocytes levels were diminished to 20% of the starting value and their value remained unchanged even after 1 year. CD45RO + CD4+ (memory) T lymphocyte levels were halved and did not recover after 1 year. After 1 year, there was still a statistically significant reduction, compared to pre-treatment values, in the levels of haemoglobin, lymphocytes, activated T lymphocytes, T lymphocytes, B lymphocytes, CD8+ and CD4+ lymphocytes, while the CD4/CD8 ratio was essentially half of that measured at T1.

The results of T-test comparing values of observed parameters at different blood sampling types are presented in Table 3.
Table 3

Comparison of the observed parameters between T1/T2, T2/T3, T1/T3, T3/T4, T1/T4, T2/T4 blood samples as p values of the t- test between compared parameters at stated blood sampling times. Statistical significant differences according to the compared value (p ≤ 0.05) are marked by * and (p ≤ 0.005) with **

 

T1/T2

T2/T3

T1/T3

T3/T4

T1/T4

T2/T4

Erci (10*12/L)

0.000**

0.000**

0.064

0.043*

0.719

0.000**

Hb (g/L)

0.000**

0.000**

0.042*

0.967

0.028*

0.000**

Leu. (10*9/L)

0.128

0.000**

0.001**

0.313

0.442

0.086

Lym (10*9/L)

0.011*

0.000**

0.000**

0.040*

0.000**

0.000**

Pt (10*9/L)

0.000**

0.000**

0.501

0.683

0.784

0.000**

Neutr (10/9/l)

0.024*

0.000**

0.192

0.443

0.887

0.131

CRP (mg/L)

0.000**

0.004**

0.223

0.707

0.466

0.001**

ESR (mm/h)

0.000**

0.000**

0.008*

0.000**

0.273

0.000**

Albumin (g/L)

0.000**

0.000**

0.049*

0.050

0.000**

0.000**

iCD64 mono.

0.011*

0.496

0.241

0.286

0.185

0.121

iCD64 nevt.

0.090

0.385

0.021*

0.008*

0.500

0.111

iCD163 mono.

0.915

0.861

0.979

0.931

0.555

0.585

iCD163 nevt.

0.378

0.618

0.164

0.725

0.297

0.683

HLA/DR3 (10*9/L)

0.989

0.534

0.436

0.002**

0.04*

0.122

CD3+ (10*9/L)

0.060

0.000**

0.000**

0.605

0.000**

0.000**

CD19+ (10*9/L)

0.006*

0.000**

0.000**

0.000**

0.000**

0.008*

CD4+ (10*9/L)

0.023*

0.000**

0.000**

0.347

0.000**

0.000**

CD8+ (10*9/L)

0.189

0.045*

0.002**

0.762

0.061

0.225

CD4/CD8

0.576

0.000**

0.000**

0.140

0.000**

0.000**

NK (10*9/L)

0.008*

0.592

0.050

0.001**

0.125

0.000**

CD45RA + CD4+

0.003**

0.000**

0.000**

0.005*

0.000**

0.000**

CD45RO + CD4+

0.045

0.000**

0.000**

0.646

0.000**

0.000**

Legend: Leu leukocytes, Lym lymphocytes, CD3+ T lymphocytes, CD19+ B lymphocytes; CD4+ T helper cells, CD8+ cytotoxic T cells, HLA/DR3 activated T lymphocytes, NK natural killer cells, iCD64 mono index of CD64 expression on monocytesm, iCD64 neutr index of CD64 expression on neutrophils, iCD163 mono index of CD163 expression on monocytes, iCD163 neutr index of CD163 expression on neutrophils, CD45 + RA + CD4+ naïve helper T lymphocytes, CD45 + RO + CD4+ memory helper T lymphocytes, CD95 + CD4+ apoptosis destined T helper cells, Erci erythrocytes, Hb haemoglobin, Pt platelets, Neutr neutrophils, ESR erythrocyte sedimentation rate, CRP C-reactive protein

One year after last blood sampling, at final check-up, we statistically correlated the measured parameters between the “success” group (no evidence of disease and death of other cause) and the “failure” group (locoregional, distant failure, secondary tumour and death of disease) at T1 for possible prognostic markers. Table 4 summarizes statistical analysis of selected parameters between both groups.
Table 4

is showing p values of the t- test at T1 between the “success” (N = 41) and the “failure” (N = 15) group of patients. Statistical significant differences according to the compared value (p ≤ 0.05) are marked by * and (p ≤ 0.005) with **

Marker

Success group

Failure Group

Significany

Normal values

CRP (mg/L)

8.5

11.0

0,496

< 5

Neutr/Lym

2.9

3.3

0,414

 

Pt (10*9/L)

277

282

0,844

140-340

CD3+ (10*9/L)

1.50

1.25

0,111

1.00-2.20

CD19+ (10*9/L)

0.17

0.16

0,717

0.11-0.57

CD45RA + CD4+

0.29

0.22

0,263

 

CD45RO + CD4+

0.66

0.60

0,391

 

Pt/Lym

153

173

0.363

 

Legend: CRP C-reactive protein, Neutr neutrophils, Lym lymphocytes, CD3+ T lymphocytes, CD19+ B lymphocytes, CD45 + RA + CD4+ naïve helper T lymphocytes, CD45 + RO + CD4+ memory helper T lymphocytes, Pt platelets

Levels of measured lymphocyte subpopulations indexed on T1 levels are shown in Fig. 1.
Fig. 1
Fig. 1

Diagram of impact of surgery and radiotherapy on lymphocyte populations (CD3+, CD19+, NK cells, CD4+, CD8+, CD45RA+, CD45RO+) indexed on T1 values

Figure 2 shows the levels of acute phase proteins (ESR, Albumin, CRP), neutrophyls and marker of activated T helpers (HLA/DR3) at blood sampling times indexed to T1 values.
Fig. 2
Fig. 2

Values of HLA/DR3, ESR, Neutrophyls, Albumin and CRP indexed to T1 levels

Discussion

Radical surgical removal of the tumour is commonly the first and most important step toward the elimination of the disease. Nonetheless, during the perioperative period in oncological surgery, there might be some shedding of malignant cells, increased proliferation of tumour cells, excess release of pro-angiogenic and/or pro-invasive factors, abundant release of growth factors, psychological distress, and suppression of cell mediated immunity, which may act in synergy to render the patient temporarily vulnerable to metastases, which could otherwise have been controlled [14].

Free tissue transfer represents one of the most popular and reliable techniques for reconstruction after large primary tumours resection [15]. In only 5 of our patients it was possible to close the defect primarily or with a local flap, all others needed distal or free flap reconstruction. During such major surgery substantial blood loss may occur, varying between 500 and 1500 ml [16]. Anaemia is expected after major surgery of the head and neck, however, moderate anaemia also developed in our patients despite the loss of small volumes of blood. Hypoxia because of anaemia can decrease radiation efficacy [17]. The level of haemoglobin in our study was just below the proposed level of Hb before RT, which is 120 g/l, although in our study blood samples were taken within 8 and 12 days after surgery, thus the expected spontaneous rise prior to radiotherapy probably did occur. Microvascular reconstruction leads to prolonged operative times, and major, prolonged, surgical procedures are known to cause immunosuppression [18].

Inflammatory proteins (ESR, CRP) are non-specific markers related to infection, injury and neoplasia. They have been also correlated to cancer progression and prognosis in different malignancies [19], which was not the case in our study. In our patients, the ESR was elevated above normal before commencement of any treatment, and doubled after surgery (T2). At the T3 blood sampling the ESR remained above the initial value but with a gradual reduction towards pre-treatment values. It is of interest that ESR at T4 fell below the starting values, although the reduction failed to reach statistical significance. C-reactive protein (CRP) is an acute phase protein synthesized in the hepatocytes. CRP levels rise approximately 4 to 12 h after surgery, and peak at 24 to 72 h [20]. Once the tissue injury is resolved, CRP levels fall rapidly due to a short half-life of 6 h. Khandavilli et al. reported that increased preoperative CRP was associated with worse overall survival in patients with oral cancer [21], but a study by Krusse et al. failed to prove any correlation between preoperative CRP levels and disease progression in head and neck cancer [22]. Our results failed to show any correlation between the preoperative levels of the CRP and disease outcome. Surgery caused a 4-fold increase in CRP levels, while at T3 the levels of CRP showed a trend of returning to the pre-treatment values, although still at more than double the normal values. This is in accordance with the study by Mohammed et al. and Cheethana et al., who used ESR and CRP as biomarkers of radiation induced mucositis [23, 24]. After 1 year the CRP levels were practically identical to the preoperative values, but still above normal, which could indicate an ever-present subtle inflammation in the radiation-damaged mucosa.

There are several reports regarding the potential utility of CD64 (Fc receptor on monocytes, neutrophils, macrophages and eosinophils) on neutrophils for the diagnostic assessment of infection and systemic inflammatory response syndrome (SIRS) in adults [25].

CD163 is a monocyte/macrophage-associated antigen, which possesses anti-inflammatory properties and has an immunoregulatory role [26]. Since both indexes are only increased for short periods of a few days [27], this might explain why we failed to find any differences in the index values at various sampling times.

Various early studies have shown that cancer patients have depressed cell-mediated immune functions [28, 29]. Although we did not use a control group to match the T1 levels with healthy volunteers, it is worth noting that the average values of our measured parameters did not fall outside of reference values used by our hospital laboratory.

Leaver et al. and Ogawa et al. reported a fall in NK cells and T lymphocytes after surgery, and the levels were reduced up to 14 days after surgery [18, 30]. Additionally, the study conducted by Kuss et al. showed a persistent reduction in CD4+ cell counts in patients with a history head and neck cancer which was discovered long after surgery [29]. In our study the levels of NK cells and CD4+ cells also fell, but in contrast with the abovementioned studies, we observed a reduction in B lymphocyte levels. There was a trend towards reduced levels of T lymphocytes, but no other measured immunological parameter reached statistical significance. Although our T2 blood samples were taken within 8 and 12 days of surgery (mean 8 ± 2), one of the reasons for this discrepancy might be the small sample group.

In our group of patients radiotherapy was delivered between 28 to 54 days after surgery (mean 34 ± 7), and it only exceeded the prescribed 6 weeks’ time in 8 patients (15%), providing the appropriate treatment regimen to most of the patients in the recommended time [31].

In our study we observed that even after more than a year, post-radiotherapy levels of lymphocytes, B lymphocytes, T lymphocytes, CD4+ and CD8+ lymphocytes remained significantly diminished compared to their pre-treatment levels. A study by Verastegui et al. [12] showed that CD4+ lymphocytes have a tendency to recover better than CD8+ cells, however, we did not see the expected trend in our study. In contrast, the levels of NK cells after a year were higher (although the increase was not statistically significant) than pre-treatment levels, indicating a probable compensatory increase. The levels of B lymphocytes in the study of Verastegui et al. [12] returned to normal after 1 year, which was not the case in our study, where they remained significantly reduced even more than a year after radiotherapy.

The large amount of accumulated evidence indicates that CD4+ T cells have a pivotal role in generating and maintaining anti-tumour immune responses through their interactions with cytotoxic T lymphocytes, B lymphocytes, macrophages and NK cells [32]. The levels of CD4+ lymphocytes more than halved after radiotherapy, and they remained at the same extremely low level even a year after radiotherapy. On the other hand, radiotherapy reduced the levels of CD8+ to 80% of pre-treatment values, and there was a trend towards the normalisation of their values a year after treatment completion, due to a faster effective doubling time of CD8+ cells, confirmed also in the study by Kuss et al. [29]. As a consequence, the CD4/CD8 index halved after radiotherapy and remained at the value of 1.1 1 year after radiotherapy. The ineffectiveness of the immune cell response mechanisms against tumour antigens may be in part due to the reduction in the number and activity of CD4+ T lymphocytes, also confirmed in our study, which impacts the function and activity of CD8+ T cells. CD4+ T cells play a key role in initiating and sustaining the CD8+ T lymphocyte-led immune responses directed against tumour cells. CD4+ T cells are important in preventing cytotoxic lymphocyte anergy, and are involved in the formation of the memory CD8+ subpopulation. They also stimulate macrophages and eosinophils present in the tumour stroma [33, 34].

Most striking was the effect of radiotherapy on naïve T lymphocytes (CD45 + RA+), whose levels plummeted to 20% of pre-treatment values in contrast to memory T lymphocytes (CD45 + RO+), whose levels merely halved after radiotherapy. Both values remained unchanged afterwards. Although the thymus was spared from radiation, probably due to partial thymus involution in elderly patients [35] and higher radiosensitivity of naïve cells [36], the reconstitution of T lymphocytes was significantly depressed. As noted before, even in the setting of exposing a small percentage of body surface to radiation therapy, when the irradiated area is rich in large blood vessels, this will cause prolonged immune alterations [12].

The immune defects of OSCC patients as well as other cancer patients are most likely due to a multitude of mechanisms, making the reversal of immune inhibition more difficult. Radiotherapy even worsens these defects, which could have a negative influence on the efficacy of RT itself and it might just be that reduced immunity induced by radiotherapy in selected group of patients within OSCC group makes them more susceptible to tumour recurrence and worse survival [12, 37].

Using biomarkers to stratify oral cancer patients’ risk of neck metastasis [38] is a rapidly developing field. We planned to search for possible markers to predict disease progression. We therefore divided patients into a treatment success and treatment failure group 2 years after radiotherapy, since recurrence most often appears within 2 years of treatment [39]. Although many authors have linked survival in head and neck cancer to many variables, such as CRP [21], lymphocyte/neutrophil ratio [40], monocytes [41] and thrombocytes [42] we did not find any correlation between pre-treatment values and disease progression or survival. The small sample size, which is the major limitation of our study, is probably the reason for this.

It should also be emphasized that the results of most of the cited publications regarding the head and neck region have dealt with a heterogeneous group of cancers, which are characterized by vastly different biological properties. Our study focused only on the immune changes in advanced squamous cell carcinoma of the oral cavity. Larger prospective studies are needed not only to confirm these findings, but also to address the possible underlying mechanisms that might link treatment-related lymphopenia to disease recurrence and survival.

Conclusions

Our study has shown that surgery causes a profound inflammatory reaction and a fall in the levels of B lymphocytes as well as NK cells, while radiotherapy produces long lasting immune depression with levels of T, B lymphocytes, CD4+ T lymphocytes and CD4/CD8 index almost halved after 1 year. Even more striking was the influence on the naïve T lymphocytes that did not recover to levels above 20% of the starting values. None of the measured parameters allowed us to predict the clinical outcome before the commencement of treatment.

Abbrevations

AOSCC: 

Advanced oral squamous cell carcinoma

CRP: 

C-reactive protein

ESR: 

Erythrocyte sedimentation rate

HNSCC: 

Head and neck squamous cell carcinoma

OSCC: 

Oral squamous cell cancers

RT: 

Radiotherapy

Declarations

Acknowledgements

Thanks to Didanovic Gorenc Nina for her proofreading and Ivan Verdenik for support regarding statistics.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Authors’ contributions

All authors contributed to the study design, read and approved the final manuscript. TD and VD treated patients. NIH and TD contributed to the writing of the manuscript. AI analyzed immunological status, while AK, MV, NIH and TD analysed results.

Ethics approval and consent to participate

This study was reviewed and approved by the Slovenian National Medical Ethics Committee, Approval No. 69/06/07. Written informed consent was obtained from all participants.

Consent for publication

Not applicable

Competing interests

None declared

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Clinical Department of Maxillofacial and Oral Surgery, |University Medical Center, Ljubljana, Slovenia
(2)
Department of Maxillofacial and Oral Surgery, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1104 Ljubljana, Slovenia
(3)
Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

References

  1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16(3):481–8.View ArticlePubMedGoogle Scholar
  2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4-5):309–16.View ArticlePubMedGoogle Scholar
  3. Amit M, Yen TC, Liao CT, Chaturvedi P, Agarwal JP, Kowalski LP, Ebrahimi A, Clark JR, Kreppel M, Zoller J, et al. Improvement in survival of patients with oral cavity squamous cell carcinoma: an international collaborative study. Cancer. 2013;119(24):4242–8.View ArticlePubMedGoogle Scholar
  4. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–9.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Lee JJ, Lin CL, Chen THH, Kok SH, Chang MC, Jeng JH. Changes in peripheral blood lymphocyte phenotypes distribution in patients with oral cancer/oral leukoplakia in Taiwan. Int J Oral Maxillofac Surg. 2010;39(8):806–14.View ArticlePubMedGoogle Scholar
  6. Gildener-Leapman N, Ferris RL, Bauman JE. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol. 2013;49(12):1089–96.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Badoual C, Sandoval F, Pere H, Hans S, Gey A, Merillon N, Van Ryswick C, Quintin-Colonna F, Bruneval P, Brasnu D, et al. Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck. 2010;32(7):946–58.PubMedGoogle Scholar
  8. Liu H, Wang SH, Chen SC, Chen CY, Lo JL, Lin TM. Immune modulation of CD4+CD25+ regulatory T cells by zoledronic acid. BMC Immunol. 2016;17(1):45.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv Otorhinolaryngol. 2005;62:161–72.PubMedGoogle Scholar
  10. Greenfeld K, Avraham R, Benish M, Goldfarb Y, Rosenne E, Shapira Y, Rudich T, Ben-Eliyahu S. Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav Immun. 2007;21(4):503–13.View ArticlePubMedGoogle Scholar
  11. Purdy J, Klein E. External photon beam dosimetry and treatment planning. Princ Pract Radiat Ther. 1997;3:308–12.Google Scholar
  12. Verastegui EL, Morales RB, Barrera-Franco JL, Poitevin AC, Hadden J. Long-term immune dysfunction after radiotherapy to the head and neck area. Int Immunopharmacol. 2003;3(8):1093–104.View ArticlePubMedGoogle Scholar
  13. Dovšak T, Ihan A, Didanovič V, Kansky A, Hren N. Influence of surgical treatment and radiotherapy of the advanced intraoral cancers on complete blood count, body mass index, liver enzymes and leukocyte CD64 expression. Radiol Oncol. 2009;43(4):282–92.Google Scholar
  14. Neeman E, Ben-Eliyahu S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun. 2013;30(Suppl):S32–40.View ArticlePubMedGoogle Scholar
  15. Omura K. Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma. Int J Clin Oncol. 2014;19(3):423–30.View ArticlePubMedGoogle Scholar
  16. Scott SN, Boeve TJ, McCulloch TM, Fitzpatrick KA, Karnell LH. The effects of Epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study. Laryngoscope. 2002;112(7):1221–9.View ArticlePubMedGoogle Scholar
  17. Grau C, Overgaard J. Significance of hemoglobin concentration for treatment outcome. In: Molls M. Vaupel P, editors. Blood perfusion and microenviroment of human tumors. Berlin: Springer; 1998. p. 101–112.Google Scholar
  18. Leaver HA, Craig SR, Yap PL, Walker WS. Lymphocyte responses following open and minimally invasive thoracic surgery. Eur J Clin Investig. 2000;30(3):230–8.View ArticleGoogle Scholar
  19. Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician. 1999;60(5):1443–50.PubMedGoogle Scholar
  20. Giannoudis PV, Smith MR, Evans RT, Bellamy MC, Guillou PJ. Serum CRP and IL-6 levels after trauma: not predictive of septic complications in 31 patients. Acta Orthop Scand. 1998;69(2):184–8.View ArticlePubMedGoogle Scholar
  21. Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol. 2009;45(10):912–4.View ArticlePubMedGoogle Scholar
  22. Kruse AL, Luebbers HT, Gratz KW. C-reactive protein levels: a prognostic marker for patients with head and neck cancer? Head Neck Oncol. 2010;2:21.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Mohammed FF, Poon I, Zhang L, Elliott L, Hodson ID, Sagar SM, Wright J. Acute-phase response reactants as objective biomarkers of radiation-induced mucositis in head and neck cancer. Head Neck. 2012;34(7):985–93.View ArticlePubMedGoogle Scholar
  24. Chethana RPS, Madathil LP, Rao S, Shetty P, Patidar M. Quantitative analysis of acute phase proteins in post chemo-radiation mucositis. J Clin Diagn Res. 2015;9(10):Zc28–31.PubMedPubMed CentralGoogle Scholar
  25. Qureshi S, Lewis S, Gant V, Treacher D, Davis B, Brown K. Increased distribution and expression of CD64 on blood polymorphonuclear cells from patients with the systemic inflammatory response syndrome (SIRS). Clin Exp Immunol. 2001;125(2):258–65.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Zuwała-Jagiełło J. Haemoglobin scavenger receptor: function in relation to disease. Acta Biochim Pol. 2005;53(2):257–68.Google Scholar
  27. Fjaertoft G, Douhan Håkansson L, Pauksens K, Sisask G, Venge P. Neutrophil CD64 (FcγRI) expression is a specific marker of bacterial infection: a study on the kinetics and the impact of major surgery. Scand J Infect Dis. 2007;39(6-7):525–35.View ArticlePubMedGoogle Scholar
  28. Olkowski ZL, Wilkins SA Jr. T-lymphocyte levels in the peripheral blood of patients with cancer of the head and neck. Am J Surg. 1975;130(4):440–4.View ArticlePubMedGoogle Scholar
  29. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10(11):3755–62.View ArticlePubMedGoogle Scholar
  30. Ogawa K, Hirai M, Katsube T, Murayama M, Hamaguchi K, Shimakawa T, Naritake Y, Hosokawa T, Kajiwara T. Suppression of cellular immunity by surgical stress. Surgery. 2000;127(3):329–36.View ArticlePubMedGoogle Scholar
  31. Graboyes EM, Garrett-Mayer E, Sharma AK, Lentsch EJ, Day TA. Adherence to National Comprehensive Cancer Network guidelines for time to initiation of postoperative radiation therapy for patients with head and neck cancer. Cancer. 2017;123(14):2651–60.View ArticlePubMedGoogle Scholar
  32. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med. 1999;189(5):753–6.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Kuss I, Donnenberg AD, Gooding W, Whiteside TL. Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. Br J Cancer. 2003;88(2):223–30.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Caserta S, Kleczkowska J, Mondino A, Zamoyska R. Reduced functional avidity promotes central and effector memory CD4 T cell responses to tumor-associated antigens. J Immunol. 2010;185(11):6545–54.View ArticlePubMedGoogle Scholar
  35. Weinberg K, Parkman R. Age, the thymus, and T lymphocytes. N Engl J Med. 1995;332(3):182–3.View ArticlePubMedGoogle Scholar
  36. Tabi Z, Spary LK, Coleman S, Clayton A, Mason MD, Staffurth J. Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer. J Immunol. 2010;185(2):1330–9.View ArticlePubMedGoogle Scholar
  37. Brown JS, Blackburn TK, Woolgar JA, Lowe D, Errington RD, Vaughan ED, Rogers SN. A comparison of outcomes for patients with oral squamous cell carcinoma at intermediate risk of recurrence treated by surgery alone or with post-operative radiotherapy. Oral Oncol. 2007;43(8):764–73.View ArticlePubMedGoogle Scholar
  38. Uchida K, Veeramachaneni R, Huey B, Bhattacharya A, Schmidt BL, Albertson DG. Investigation of HOXA9 promoter methylation as a biomarker to distinguish oral cancer patients at low risk of neck metastasis. BMC Cancer. 2014;14:353.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Kissun D, Magennis P, Lowe D, Brown JS, Vaughan ED, Rogers SN. Timing and presentation of recurrent oral and oropharyngeal squamous cell carcinoma and awareness in the outpatient clinic. Br J Oral Maxillofac Surg. 2006;44(5):371–6.View ArticlePubMedGoogle Scholar
  40. Fang HY, Huang XY, Chien HT, Chang JT, Liao CT, Huang JJ, Wei FC, Wang HM, Chen IH, Kang CJ, et al. Refining the role of preoperative C-reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinoma. Laryngoscope. 2013;123(11):2690–9.View ArticlePubMedGoogle Scholar
  41. Bobdey S, Ganesh B, Mishra P, Jain A. Role of monocyte count and neutrophil-to-lymphocyte ratio in survival of oral cancer patients. Int Arch Otorhinolaryngol. 2017;21(1):21–7.PubMedGoogle Scholar
  42. Lu CC, Chang KW, Chou FC, Cheng CY, Liu CJ. Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol. 2007;43(3):283–8.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement